From Our 2014 Archives
Zontivity Approved For People at High-Risk of Heart Attack, Stroke
Latest Heart News
The drug is the first in a new class called protease-activated receptor-1 antagonists, designed to weaken the tendency of platelets to clump and form a blood clot. But the agency said the drug increases users' risks of developing life-threatening bleeding. Zontivity's label includes a boxed warning describing this risk, the FDA said Thursday in a news release.
The drug is meant for people who have had a previous heart attack or blocked arteries in the arms or legs. It should not be used by people who have had a prior stroke, "mini-stroke" or a prior episode of bleeding in the head, the agency warned.
The most common side effects include bleeding and bruising. Users who have these side effects should report them immediately to their doctors, the FDA advised.
Zontivity is made by Merck Sharp and Dohme Corp., whose parent Merck & Co. is based in Whitehouse Station, N.J.
-- Scott Roberts
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions